PFIZER'S CTI REQUESTS PROPOSALS FOR SMALL-MOLECULE TARGETS

Pre-Proposal Deadline: October 16, 2015

CTI, or **Pfizer's Centers for Therapeutic Innovation**, is a unique program that partners with leading academic medical centers and foundations nationwide in an effort to speed the translation of novel targets to the clinic. CTI's goal is to identify new compounds and accelerate research from validated target to proof-of-mechanism in the clinic.

Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer's technologies and compound library, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

CTI's foundation partners include:

- Alliance for Lupus Research
- Alzheimer's Drug Discovery Foundation
- Crohn's and Colitis Foundation of America

Pre-proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

New Initiative: CTI's Small-molecule Accelerator

- **In addition to the usual small-molecule request for proposals, CTI is introducing a Small Molecule Accelerator (SMA)" initiative**
- **The CTI SMA program is based on a select set of characterized lead-like small-molecule compounds with activity and selectivity for established targets**
- **The compounds within the SMA:**
  - **Are selective pharmacological modulators representative of a lead quality series (Details regarding small molecule inhibitors included in the SMA will be shared upon request); and**
  - **Are suitable for cell-based target validation assays at a minimum; some are suitable for preclinical in-vivo experiments; and may have been through in-vivo toxicology screens**
- **Proposals must delineate a plan to evaluate one or a small number of these compounds in a specific assay in the laboratory of the Investigator, evaluating a target-related hypothesis**

All researchers and clinicians whose work meets these criteria are invited to apply. **Please submit pre-proposals to Nate Hafer (nathaniel.hafer@umassmed.edu) by October 16, 2015.**
For more details, please Venkat Reddy (Venkateshwar.reddy@pfizer.com) or Nathaniel Hafer (nathaniel.hafer@umassmed.edu)

CTI
Centers for Therapeutic Innovation
www.PfizerCTI.com

COLLABORATIVE ENTREPRENEURIAL RESULTS-DRIVEN

CTI Small Molecule Accelerator

List of Biological Target/Class

Biological Target	Class
CREB binding protein bromodomain inhibitor	Bromodomain
LYPLA1 inhibitor	Serine hydrolase
Neutral endopeptidase inhibitor	Metallo-protease
Selective androgen receptor modulator	Nuclear hormone receptor
GPR119 agonist	GPCR
GPR44 (CRTH2) antagonist	GPCR
KATII (Aminoadipate aminotransferase) inhibitor	Amino-transferase
NaCT	SLC
PDE1 inhibitor	PDE
PDE7 inhibitor	PDE
PDE8 inhibitor	PDE
PDE11 inhibitor	PDE
pan MARK inhibitor	Kinase

Biological Target	Class
LTK inhibitor	Kinase
TYRO3 (SKY) inhibitor	Kinase
PIK3C2A inhibitor	Kinase
PI3K/mTOR inhibitor	Kinase
MAP4K4 inhibitor	Kinase
ASK1 inhibitor	Kinase
RIP1 inhibitor	Kinase
ITK allosteric inhibitor	Kinase
V1a antagonist	GPCR
Thrombin activatable fibrinolysis inhibitor (TAFIa)	Carboxy peptidase
hPGDS inhibitor	GST
ASIC1a antagonist	Ion channel
P2X3 inhibitor	Ion channel
P2X4 inhibitor	Ion channel